"Out with the old! Be it the fresh start of a new year or a spring cleaning, consumers are encouraged to take stock of what has surpassed its usefulness. Medicines are no exception.
In 1979, the U.S. Food and Drug Administration (FDA) began "...
BeneFIX Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
BeneFIX, Coagulation Factor IX (recombinant) is a man-made protein similar to a natural protein in the body that helps the blood to clot used to treat or prevent bleeding in people with hemophilia B. BeneFIX is not for treating people with hemophilia A factor VII deficiency. Common side effects of BeneFIX include fever, injection site reactions (pain, redness, or swelling), chills, headache, flushing (warmth, redness, or tingly feeling under your skin), weakness, nausea, vomiting, or dizziness.
Dosage and duration of treatment for all factor IX products depends on the severity of the factor IX deficiency, the location and extent of bleeding, and the patient's clinical condition, age and recovery of factor IX. Other drugs may interact with BeneFIX. Tell your doctor all medications and supplements you use. During pregnancy, BeneFIX should be used only when prescribed. It is unknown if this medication passes into breast milk. Consult your doctor before breastfeeding.
Our BeneFIX, Coagulation Factor IX (recombinant) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
BeneFIX in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
- fever or chills;
- continued bleeding after treatment;
- feeling like you might pass out;
- sudden numbness or weakness, especially on one side of the body;
- sudden headache, confusion, problems with vision, speech, or balance; or
- swelling in your feet or ankles, weight gain, loss of appetite.
Less serious side effects may be more likely to occur, such as:
- warmth, redness, or tingly feeling under your skin;
- nausea, vomiting;
- dizziness; or
- pain, redness, or swelling where the medicine was injected.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for BeneFIX (Coagulation Factor IX Recombinant for Injection)
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
BeneFIX Overview - Patient Information: Side Effects
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor right away if you have any serious side effects, including: swelling at injection site, shortness of breath, fast heartbeat, change in the amount of urine, swelling of the ankles/feet, pain/redness/swelling of arms or legs, new or increased bleeding/bruising.
Get medical help right away if any of these rare but very serious side effects occur: bluish fingers, chest pain, trouble breathing.
A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for BeneFIX (Coagulation Factor IX Recombinant for Injection)
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
BeneFIX FDA Prescribing Information: Side Effects
The most serious adverse reactions are systemic hypersensitivity reactions, including bronchospastic reactions and/or hypotension and anaphylaxis and the development of high-titer inhibitors necessitating alternative treatments to factor IX replacement therapy.
The most common adverse reactions observed in clinical trials (frequency > 5% of PTPs or PUPs) were headaches, dizziness, nausea, injections site reaction, injection site pain and skin-related hypersensitivity reactions (e.g., rash, hives).
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
During uncontrolled, open-label clinical studies with BeneFIX conducted in previously treated patients (PTPs), 113 adverse reactions with known or unknown relation to BeneFIX therapy were reported among 38.5% (25 of 65) of subjects (with some subjects reporting more than one event) who received a total of 7,573 infusions. These adverse reactions are summarized in Table 2.
Table 2: Adverse Reactions Reported for PTPs*
|Body System||Adverse Reaction||Number of patients (%)|
|Blood and lymphatic system disorders||Factor IX inhibition†||1 (1.5%)|
|Eye disorders||Blurred vision||1 (1.5%)|
|Gastrointestinal disorders||Nausea||4 (6.2%)|
|General disorders and administration
|Injection site reaction||5 (7.7%)|
|Injection site pain||4 (6.2%)|
|Infections and infestations||Cellulitis at IV site||1 (1.5%)|
|Phlebitis at IV site||1 (1.5%)|
|Nervous system disorders||Taste perversion (altered taste)||3 (4.6%)|
|Renal and urinary disorders||Renal infarct‡||1 (1.5%)|
|Respiratory, thoracic and mediastinal
|Dry cough||1 (1.5%)|
|Chest tightness||1 (1.5%)|
|Skin and subcutaneous disorders||Rash||4 (6.2%)|
|Vascular disorders||Flushing||2 (3.1%)|
|*Adverse reactions reported within 72 hours of an
infusion of BeneFIX.
†Low-titer transient inhibitor formation.
‡The renal infarct developed in a hepatitis C antibody-positive patient 12 days after a dose of BeneFIX for a bleeding episode. The relationship of the infarct to the prior administration of BeneFIX is uncertain.
In the 63 previously untreated patients (PUPs), who received a total of 5,538 infusions, 10 adverse reactions were reported among 9.5% of the patients (6 out of 63) having known or unknown relationship to BeneFIX. These events are summarized in Table 3.
Table 3: Adverse Reactions Reported for PUPs*
|Body System||Adverse Reaction||Number of Patients (%)|
|Blood and lymphatic system disorders||Factor IX inhibition†||2 (3.2%)|
|General disorders and administration site||Injection site reaction||1 (1.6%)|
|Respiratory, thoracic and mediastinal disorders||Dyspnea (respiratory distress)||2 (3.2%)|
|Skin and subcutaneous disorders||Hives||3 (4.8%)|
|*Adverse reactions reported within 72 hours of an
infusion of BeneFIX.
†Two subjects developed high-titer inhibitor formation during treatment with BeneFIX.
In clinical studies with 65 PTPs (defined as having more than 50 exposure days), a low-titer inhibitor was observed in one patient. The inhibitor was transient, the patient continued on study and had normal factor IX recovery pharmacokinetics at study completion (approximately 15 months after inhibitor detection).
In clinical studies with pediatric PUPs, inhibitor development was observed in 2 out of 63 patients (3.2%), both were high-titer ( > 5 BU) inhibitors detected after 7 and 15 exposure days, respectively. Both patients were withdrawn from the study.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to BeneFIX with the incidence of antibodies to other products may be misleading.
All subjects participating in the PTP, PUP and surgery studies were monitored for clinical evidence of thrombosis. No thrombotic complications were reported in PUPs or surgery subjects. One PTP subject experienced a renal infarct (see Table 2). Laboratory studies of thrombogenecity (fibrinopeptide A and prothrombin fragment 1 + 2) were obtained in 41 PTPs and 7 surgery subjects prior to infusion and up to 24 hours following infusion. The results of these studies were inconclusive. Out of 29 PTP subjects noted to have elevated fibrinopeptide A levels post-infusion of BeneFIX, 22 also had elevated levels at baseline. Surgery subjects showed no evidence of significant increase in coagulation activation.
The following post-marketing adverse reactions have been reported for BeneFIX: inadequate factor IX recovery, inadequate therapeutic response, inhibitor development [see CLINICAL PHARMACOLOGY], anaphylaxis [see WARNINGS AND PRECAUTIONS], angioedema, dyspnea, hypotension, and thrombosis.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
There have been post-marketing reports of thrombotic events, including life-threatening SVC syndrome in critically ill neonates, while receiving continuous-infusion BeneFIX through a central venous catheter. Cases of peripheral thrombophlebitis and DVT have also been reported. In some, BeneFIX was administered via continuous infusion, which is not an approved method of administration [see DOSAGE AND ADMINISTRATION]. The safety and efficacy of BeneFIX administration by continuous infusion have not been established [see WARNINGS AND PRECAUTIONS].
Read the entire FDA prescribing information for BeneFIX (Coagulation Factor IX Recombinant for Injection)
Additional BeneFIX Information
Benefix - User Reviews
Benefix User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.